Tempest Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TPST research report →
Companywww.tempesttx.com
Tempest Therapeutics Inc. , a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors.
- CEO
- Matthew Angel
- IPO
- 2012
- Employees
- 24
- HQ
- Brisbane, CA, US
Price Chart
Valuation
- Market Cap
- $8.26M
- P/E
- -0.47
- P/S
- 0.00
- P/B
- 24.74
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -729.89%
- ROIC
- -499.76%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,262,000 · 37.24%
- EPS
- $-6.33 · -322.00%
- Op Income
- $-26,575,000
- FCF YoY
- 19.85%
Performance & Tape
- 52W High
- $12.23
- 52W Low
- $1.50
- 50D MA
- $1.93
- 200D MA
- $5.29
- Beta
- -1.69
- Avg Volume
- 209.48K
Get TickerSpark's AI analysis on TPST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Trojanowski Justin | other | 22,000 |
| Mar 31, 26 | Maestas Nicholas | other | 140,000 |
| Mar 24, 26 | Angel Matthew | buy | 231,482 |
| Feb 4, 26 | Angel Matthew | other | 269,621 |
| Feb 3, 26 | Angel Matthew | other | 0 |
| Jan 27, 26 | Simantov Ronit | other | 1,230 |
| Jan 27, 26 | NICHOL GEOFFREY | other | 1,230 |
| Jan 27, 26 | RAAB MICHAEL | other | 1,230 |
| Jan 27, 26 | Pellizzari Christine A | other | 1,230 |
| Jan 2, 25 | Brady Stephen R | other | 550,000 |
Our TPST Coverage
We haven't published any research on TPST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TPST Report →